Peptide - Switzerland

Samsung Biologics Acquires Swiss CDMO for approximately $1.8 Billion, Making a Major Push into the Obesity Drug Market — BigGo Finance

Read More

Samsung Biologics Acquires Swiss CDMO for approximately $1.8 Billion, Making a Major Push into the Obesity Drug Market — BigGo Finance

2026-07-22

Samsung Biologics (207940) is investing approximately 2.7 trillion won (approximately $1.8 billion) to acquire PolyPeptide Group, a global…

Samsung Biologics Bets $1.8 Billion on 'K-Obesity Drug' Play with Swiss PolyPeptide Acquisition — BigGo Finance

Read More

Samsung Biologics Bets $1.8 Billion on ‘K-Obesity Drug’ Play with Swiss PolyPeptide Acquisition — BigGo Finance

2026-07-21

Samsung Biologics has thrown its hat into the rapidly growing global obesity treatment market, committing 2.7 trillion won…

MASH dash speeds up as Roche acquires 89bio for up to $3.5B

Read More

MASH dash speeds up as Roche acquires 89bio for up to $3.5B

2026-02-18

The dash for MASH is gaining momentum, with Roche AG acquiring 89bio Inc. and its phase III FGF21…